/COCP
COCP Stock - Cocrystal Pharma, Inc.
Healthcare|BiotechnologyNASDAQ
$0.99-1.00%
$0.01 (-1.00%) • Dec 19
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.9
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.78
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.09
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for COCP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.98 – $1.00
TARGET (TP)$1.14
STOP LOSS$0.91
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.05
52W High$3.26
52W Low$0.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $2.01M |
| Gross Profit | $-12,537,000 | $-15,169,000 | $-12,392,000 | $-8,794,000 | $-4,020,000 |
| Gross Margin | N/A | N/A | N/A | N/A | -199.6% |
| Operating Income | $-17,878,000 | $-18,559,000 | $-38,829,000 | $-14,221,000 | $-9,586,000 |
| Net Income | $-17,504,000 | $-17,984,000 | $-38,837,000 | $-14,185,000 | $-9,648,000 |
| Net Margin | N/A | N/A | N/A | N/A | -479.0% |
| EPS | $-1.72 | $-0.00 | $-4.77 | $-1.85 | $-2.01 |
Company Overview
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
COCPBeat Rate
53%
Last 19 quarters
Avg Surprise
+10.3%
EPS vs Estimate
Beats / Misses
10/3
6 met exactly
Latest EPS
$-0.19
Q4 2025
EPS Surprise History
Q1 24
+22.8%
$-0.44vs$-0.57
Q2 24
+27.8%
$-0.39vs$-0.54
Q3 24
-3.9%
$-0.53vs$-0.51
Q4 24
+14.0%
$-0.49vs$-0.57
Q1 25
+41.8%
$-0.32vs$-0.55
Q2 25
+55.8%
$-0.23vs$-0.52
Q3 25
+33.3%
$-0.20vs$-0.30
Q4 25
+13.6%
$-0.19vs$-0.22
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.18 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.22 | $-0.19 | +13.6% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.30 | $-0.20 | +33.3% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.52 | $-0.23 | +55.8% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-0.55 | $-0.32 | +41.8% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.57 | $-0.49 | +14.0% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.51 | $-0.53 | -3.9% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.54 | $-0.39 | +27.8% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-0.57 | $-0.44 | +22.8% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.47 | $-0.41 | +12.8% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.53 | $-0.50 | +5.7% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.59 | $-0.64 | -8.5% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $-0.72 | $-0.55 | +23.6% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.49 | $-0.70 | -42.9% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.48 | $-0.48 | 0.0% | = MET |
Q2 2022 | May 11, 2022 | $-0.48 | $-0.48 | 0.0% | = MET |
Q1 2022 | Mar 23, 2022 | $-0.48 | $-0.48 | 0.0% | = MET |
Q4 2021 | Nov 15, 2021 | $-0.48 | $-0.48 | 0.0% | = MET |
Q3 2021 | Aug 16, 2021 | $-0.48 | $-0.48 | 0.0% | = MET |
Q2 2021 | May 17, 2021 | $-0.48 | $-0.48 | 0.0% | = MET |
Latest News
Cocrystal Pharma Receives IRB Approval From Emory University School Of Medicine For Phase 1b Human Challenge Study With CDI-988 In Prevention And Treatment of Norovirus
📈 PositiveBenzinga•Dec 18, 2025, 01:07 PM
Cocrystal Pharma Expects To Initiate CDI-988 Phase 1b Norovirus Challenge Study In Q1 2026
➖ NeutralBenzinga•Nov 14, 2025, 01:29 PM
Cocrystal Pharma Q3 EPS $(0.19) Beats $(0.21) Estimate
📈 PositiveBenzinga•Nov 14, 2025, 01:27 PM
Cocrystal Pharma Awarded Roughly $500K Phase 1 Award From National Institutes of Health's National Institute of Allergy and Infectious Diseases To Support Development Of Antiviral Candidate To Treat Influenza A And B Infections
📈 PositiveBenzinga•Oct 27, 2025, 12:04 PM
Cocrystal Pharma Reveals Up To $13M Registered Direct Offering
➖ NeutralBenzinga•Sep 12, 2025, 01:53 PM
Cocrystal Pharma shares are trading higher after the company presented CDI-988 as its first oral antiviral candidate for Norovirus at the 9th International Calicivirus Conference.
📈 PositiveBenzinga•Sep 12, 2025, 12:35 PM
Cocrystal Pharma Highlights CDI-988 As First Oral Antiviral Candidate For Norovirus At 9th International Calicivirus Conference
📈 PositiveBenzinga•Sep 12, 2025, 12:02 PM
Artelo Biosciences Announces Publication Of New Preclinical Data On ART12.11, Proprietary Cannabidiol:tetramethylpyrazine Cocrystal
📈 PositiveBenzinga•Sep 10, 2025, 12:36 PM•Also:
Cocrystal Pharma Receives Study May Proceed Letter From FDA To Conduct Phase 1b Challenge Study Evaluating CDI-988 For Prevention And Treatment Of Norovirus Infections; Phase 1b Challenge Study Is Planned To Begin Before Year-End 2025
📈 PositiveBenzinga•Sep 8, 2025, 12:01 PM
Cocrystal Pharma Narrows Loss in Q2
📈 PositiveThe Motley Fool•Aug 14, 2025, 12:13 PM
Frequently Asked Questions about COCP
What is COCP's current stock price?
Cocrystal Pharma, Inc. (COCP) is currently trading at $0.99 per share. The stock has moved -1.00% today.
What is the analyst price target for COCP?
No analyst price targets are currently available for this stock.
What sector is Cocrystal Pharma, Inc. in?
Cocrystal Pharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is COCP's market cap?
Cocrystal Pharma, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does COCP pay dividends?
No, Cocrystal Pharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBOLT
Bolt Biotherapeutics, Inc.
$5.16
Mkt Cap: $0.0B
BRTX
BioRestorative Therapies, Inc.
$1.15
Mkt Cap: $0.0B
CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
DWTX
Dogwood Therapeutics, Inc.
$6.45
Mkt Cap: $0.0B
EVGN
Evogene Ltd.
$1.02
Mkt Cap: $0.0B
IMNN
Imunon, Inc.
$3.75
Mkt Cap: $0.0B
IMRN
Immuron Limited
$0.94
Mkt Cap: $0.0B
MRKR
Marker Therapeutics, Inc.
$1.28
Mkt Cap: $0.0B
SNSE
Sensei Biotherapeutics, Inc.
$8.86
Mkt Cap: $0.0B
TRAW
Traws Pharma, Inc.
$1.27
Mkt Cap: $0.0B
Explore stocks similar to COCP for comparison